Press Releases Back to Home Page

Printer Friendly Version

Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

BRIDGEWATER, N.J. (July 30th, 2012) – Senesco Technologies, Inc. (“Senesco” or

the “Company”) (NYSE MKT: SNT) reported today that it was informed on July 26th that

the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for

the company’s lead drug candidate SNS01-T for treatment of both mantle cell

lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). As a result, the company

is eligible to receive a number of benefits, including tax credits, access to grant funding

for clinical trials, accelerated FDA approval, allowance for marketing exclusivity after

drug approval for a period of as long as seven years and potential exemption from the

FDA's prescription drug application fee.

“We are pleased mantle cell and diffuse large B-cell lymphomas join multiple myeloma

on the list of cancers for which SNS01-T has been granted orphan-drug status by the

FDA,” said Leslie J. Browne, Ph.D., Senesco’s Chief Executive Officer. “SNS01-T was

designed to selectively trigger cell death in B-cell malignancies. Obtaining orphan-drug

status for these cancers is complemented by the efficacy of SNS01-T in mouse models

of MCL and DLBCL as well as our plans to evaluate the effectiveness of SNS01-T in

patients with these cancers.”

The effects of SNS01-T in mouse models of MCL and DLBCL was presented orally on

Thursday, May 17th, 2012 during the “Cancer-Targeted Gene & Cell Therapy” session at

the 15th Annual Meeting of American Society of Gene & Cell Therapy in Philadelphia,

PA.

The United States Orphan Drug Act of 1983 was created to promote the development of

new drug therapies for the treatment of diseases that affect fewer than 200,000

individuals in the United States.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger

apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large

B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively

enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for

Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in

Morgantown, WV. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-

T&rank=1

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell

derived from B-lymphocytes, normally responsible for the production of antibodies, in

which abnormal cells accumulate in the bone marrow leading to bone lesions and

interfering with the production of normal blood cells. Senesco was previously granted

orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of

multiple myeloma.

About Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a form of non-Hodgkin lymphoma (NHL), constituting

roughly 6 percent of all NHL cases in the United States. It is considered an aggressive

form of B-cell lymphoma. The prevalence of MCL in the United States is approximately

27,000 patients.

About Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma

(NHL) accounting for up to 30 percent of newly diagnosed cases. DLBCL is a fastgrowing

B-cell lymphoma that can arise in lymph nodes or outside of the lymphatic

system in several organs. It can progress rapidly if untreated. The prevalence of DLBCL

in the United States is approximately 137,000 patients

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is running a clinical study in multiple myeloma

with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively

inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A),

which is believed to be an important regulator of cell growth and cell death. Accelerating

apoptosis may have applications in treating cancer, while delaying apoptosis may have

applications in treating certain inflammatory and ischemic diseases. Senesco has

already partnered with leading-edge companies engaged in agricultural biotechnology

and biofuels development, and is entitled to earn research and development milestones

and royalties if its gene-regulating platform technology is incorporated into its partners’

products. www.senesco.com

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a

variety of factors, including, but not limited to: the ability of the Company to consummate

additional financings; the Company’s ability to recruit and enroll patients in its clinical

trial; the development of the Company’s gene technology; the approval of the

Company’s patent applications; the successful implementation of the Company’s

research and development programs and collaborations; the success of the Company's

license agreements; the acceptance by the market of the Company’s products; the

timing and success of the Company’s preliminary studies, preclinical research and

clinical trials; competition and the timing of projects and trends in future operating

performance, the Company’s ability to comply with the continued listing standards of the

NYSE Amex, as well as other factors expressed from time to time in the Company’s

periodic filings with the Securities and Exchange Commission (the "SEC"). As a result,

this press release should be read in conjunction with the Company’s periodic filings with

the SEC. The forward-looking statements contained herein are made only as of the date

of this press release, and the Company undertakes no obligation to publicly update

such forward-looking statements to reflect subsequent events or circumstances.

Contact:

Company:

Senesco Technologies, Inc.

Leslie J. Browne, Ph.D., 908-864-4444

President & CEO

or

Investor Relations:

CEOcast, Inc.

Robert Woods 212-732-4300

rwoods@ceocast.com